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Poster Session-II 133(cGVHD) was 54% and 34%, respectively. Probability of OS was
62% (CI95: 48.3–78.4). There was .10-fold interpatient variability
in AUC0-6 and MPA trough (C0). Mean PK are shown in Table 1.
Table 1. Mean pK Parameters
MMF PO MMF POIV MMF administration 1st sample 2nd sampleMean pK
valuesDay 11
(SD) [N527]Day 17
(SD) [N531]Day 114
(SD) [N532]Day 145-100
(SD) [N515]Day 145-100
(SD) [N59]Cmax (mg/L) 15.4 (19.71) 12.31 (7.99)
J 16.54 (13.24)J 13.15 (12.04) 13.20 (8.86)Tmax (h) 1.87 (0.47) 1.92 (0.55) 1.75 (0.44) 1.7 (0.98) 1.33 (0.83)C0 (mg/L) 0.33 (0.29)* 0.68 (0.56)* 0.72 (0.62) 1.45 (1.46) 1.43 (1.37)Css (mg/L) 5.45 (6.34) 4.73 (2.22) 6.46 (4.07) 5.38 (3.55) 6.54 (3.55)AUC0-6
(mgh/L)
32.06 (38.09) 26.82 (12.35)J 33.71 (16.86)J 26.50 (19.03) 26.70 (15.81)CLss (L/hkg) 1.46 (1.04) 1.40 (0.63) * 1.17 (0.63) * 2.21 (1.43) 1.46 (1.01)
Vss (L/kg) 3.04 (1.91) 3.35 (1.58)
l 3.00 (2.05)l 9.77 (8.93) 18.33 (35.74)T1/2 (h) 1.02 (0.69) 1.35 (1.01) 2.49 (6.77) 3.17 (2.63) 10.19 (18.06)*P50.002.
JP50.0003.
lP50.001
MPA steady state clearance (CLss) (cohort 1 vs 2 vs 3 5 1.65 vs
1.45 vs 0.88 L/h$kg, P 5 0.0039) and volume of distribution (Vss)
(cohort 1 vs 2 vs 3 5 3.87 vs 3.22 vs 2.44 L/kg, P 5 0.052) were
higher in pts\6 yrs. There was also a trend toward higher CLss in
pts receiving MA vs NMA (1.55 vs 1.15 L/h$kg, P 5 0.054). There
was a significant difference in most PK values on Day 17 vs Day
114: higher AUC0-6 & Cmax and decreased CLss & Vss on Day
114 (Table 1). These differences suggest improved mucosal healing
and/or increased enterohepatic recirculation on Day 114 vs 17.
Mean MPA Css in this study was significantly higher (.5 mg/L)
than previously reported in other adult and pediatric AlloSCT trials
(1.6–4.8 mg/L) (Nash et al, 2005; Jacobson et al 2008). This can be
explained by .2-fold higher dose of MMF (30 mg/kg q6h) com-
pared to others (15 mg/kg q6-8h). The incidence of aGVHD and
cGVHD were comparable to previous reports. These results suggest
a need for more frequent (q6h) MMF dosing in pediatric AlloSCT
recipients, especially those\6 years. However, the optimal MMF
dose (mg/kg) and relationship between MPA exposure and risk of
acute GVHD remain to be elucidated.371
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Background: Therapy of acute intestinal GVHD is routinely
treated with immunosuppressive agents, including systemic cortico-
steroids. Several reports have shown responses of using ‘‘topical’’
therapy with budesonide for GI GVHD. Budesonide is a potent ste-
roid with low oral bioavailability due to high first pass metabolism by
CYP 3A4. In patients with Crohn’s disease, bioavailability is approx-
imately 10–20%. No data are available in hematopoeitic stem cell
transplant recipients. Several reports using budesonide for the treat-
ment of GI GVHD have noted responses in other GVHD sites, thus
questioning if active absorption was occurring. As a quality measure
at our center, several patients who had GI GVHD and/or C. Difficile
were evaluated for systemic availability of budesonide.
Methods: Random plasma budesonide levels were analyzed by
HPLC/Mass Spectrometry in 8 patients with a history of GI
GVHD receiving Enterocort brand of budesonide.
Results: A total of 11 budesonide plasma levels were measured in
8 patients. Seven patients had active GVHD, 5 patients had active
GVHD and concurrent C. Difficile infection, and 2 patients had
C. Difficile without active GVHD at the time of plasma measure-
ments. Four of the 8 levels were measured on a budesonide dose of
9 mg TID, two on 9 mg once daily, three on 6 mg TID, and twoon 3 mg TID. The mean budesonide plasma level was 0.86 mcg/dl
(0.08–1.5), 0.60 mcg/dl (0.09–1.1), 0.97 mcg/dl (0.2 – 1.1) and 0.65
mcg/dl (0.2–1.1) respectively. Mean budesonide levels were higher
if patients were on voriconazole (1.05 mcg/dl) than on micafungin
(0.47 mcg/dl). The mean budesonide bioavailability was 37% in all
patients and 50% if on Voriconazole. Thus, budesonide doses rang-
ing from 3 mg TID to 9 mg TID would represent a potency equiv-
alent to 40–162 mg methylprednisolone/day.
Conclusion: Systemic budesonide levels were significantly ele-
vated in patients with acute GI GVHD. Patients on voriconazole
had higher plasma levels of budesonide, possibly attributable to
CYP450 inhibition. The use of oral budesonide in patients with gas-
tro-intestinal GVHD may lead to systemic absorption and subse-
quent additive systemic corticosteroid effects.IMMUNE RECONSTITUTION372
THYMIC EPITHELIAL CELLS AND DENDRITIC CELLS MEDIATE THYMIC
RENEWAL THROUGH CCL25 PRODUCTION
Williams, K.M., Lucas, P.J., Bare, C.V., Wang, J., Mella, H.A.,
Gress, R.E. National Cancer Institute/NIH, Bethesda, MD
Impaired thymopoiesis contributes to immune deficiency follow-
ing hematopoeitic stem cell transplantation (HSCT). Clinical data
suggest that thymic epithelial cell (TEC) damage from the prepara-
tive regimen may compromise thymic recovery. We have previously
shown that TEC are critical for thymic renewal in the setting of an-
drogen withdrawal. These UEA1 medullary TEC provide a niche
for early thymic progenitor (ETP) entry and thymocyte development
by increasing the production of CCL25. Following androgen with-
drawal, CCL25 accelerates thymocyte development and enhances
ETP entry. Blockade of this ligand completely abrogates these af-
fects, preventing thymic renewal. We now demonstrate that cytotoxic
preparative regimens may impair thymic reconstitution by damaging
stroma, decreasing CCL25 availability. In this study, we examined
the effects of cyclophosphamide (CY) (240 mg/kg/mouse) or total
body irradiation in female mice on TEC and medullary dendritic
cell (mDC) populations and CCL25 production. At 1⁄2 myeloablative
dose of 750 cGy, using flow cytometry of TEC, we show that both CY
and radiation significantly deplete UEA1 medullary TEC while
sparing Ly511CD45- cells. However, the effects of these two agents
differed with regards to the proportions of TEC within the Ly511
fraction. Radiation led to an increase in fibroblasts (CD45- Ly511
MHCII-) with a marked reduction of cortical TEC (CD45- Ly511
MHCII1), while this TEC subset was spared following CY adminis-
tration. Furthermore, mDC were decreased following radiation
while unaffected by CY. After irradiation, these alterations signifi-
cantly impair CCL25 production as shown by decreased mRNA pro-
duction of TEC enriched preparations and thymocyte fractions (in
which only mDC produce CCL25). In contrast, CCL25 production
was unaffected following CY administration, consistent with the hy-
pothesis that the spared TEC populations preserve CCL25 produc-
tion. These data suggest that cytotoxic preparative regimens may
impair thymic renewal by destroying TEC and mDC populations
thereby reducing available CCL25, a ligand necessary and essential
for thymic recovery. Furthermore, these data suggest that different
preparative regimens may impair thymic recovery to varying degrees
due to discrimination of injured TEC and mDC populations, and the
preservation of thymic CCL25 production. Investigation of alterna-
tive preparative regimen agents may present an opportunity to im-
prove thymic renewal following HSCT.373
HUMAN COLON CARCINOMA CELLS EXPRESSING CMVPP65 ANTIGEN:
AN IN-VIVO MODEL FOR ADOPTIVE IMMUNOTHERAPY OF CMV DISEASE
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Adoptive transfer of large doses of CMV-specific T cells (CMV-
CTL) can effectively prevent CMV disease in HSCT recipients.
However, data regarding the relative potency of T cells (TC) specific
